LadRx Stock Price, News & Analysis

LadRx (OTCQB: LADX) and ImmunityBio have agreed to mutually terminate the aldoxorubicin license, returning control of the drug to LadRx. This move follows LadRx's 2023 transfer of royalty and milestone rights of aldoxorubicin to XOMA for $5 million upfront, potentially up to $7 million more in milestones. XOMA has consented to the termination and will receive a low-single-digit synthetic royalty on aldoxorubicin and a mid-single-digit percentage from future out-license agreements. Aldoxorubicin, part of LadRx's LADR-based drug program, has shown promise in clinical trials with lower cardiotoxicity compared to doxorubicin. LadRx plans to review aldoxorubicin's data for further clinical development and expects to file an IND for another drug, LADR-7, by late 2024.

LadRx Corporation (OTCQB: LADX) has been granted a patent by the USPTO for its maytansinoid-based drug delivery systems. This innovation aims to enhance the delivery of chemotherapeutic agents, allowing for nearly 10 times the dosing of traditional methods. The company's lead drug candidate, Aldoxorubicin, is out-licensed to Immunity Bio, Inc., currently undergoing clinical trials for pancreatic cancer. LadRx's next-generation drugs, LADR7-10, are poised to enter IND-enabling activities and could be ready for Phase 1 trials within 18 months. The patent solidifies LadRx's IP portfolio, supporting its cancer treatment initiatives.

LadRx Corporation (OTCQB: LADX) has initiated a strategic review to maximize shareholder value, exploring options like mergers, financing, and potential stock splits for NASDAQ up-listing. CEO Stephen Snowdy emphasized the potential of Arimoclomol and Aldoxorubicin, along with next-generation oncology drugs. The rights to Arimoclomol were sold to Zevra Therapeutics, which may bring up to $120M in milestones if successful in FDA submissions. Aldoxorubicin could generate up to $343M through Immunity Bio, which is advancing clinical trials. The Company has engaged Roth Capital Partners for advisory support during this review process.

LadRx Corporation (OTCQB: LADX) provides a quarterly update for Q3 2022, highlighting its biopharmaceutical advancements, particularly in cancer therapeutics. The company focuses on its LADR technology, enabling targeted chemotherapeutic delivery. Key developments include the next-gen LADR drug candidates LADR7-10 and the progress of Aldoxorubicin, now in clinical trials under Immunity Bio (NASDAQ: IBRX). Financially, LadRx aims to extend its cash runway into mid-2023 while seeking additional funding amidst challenging market conditions.

LadRx Corporation (OTCQB: LADX) has announced a change in its OTCQB ticker symbol from CYTR to LADX, effective October 6, 2022. This decision aligns with the company's rebranding efforts, including its name change earlier this year. CEO Stephen Snowdy emphasized that the new symbol reflects the company's focus on its unique product platform, which includes the clinical drug Aldoxorubicin and four pre-clinical cancer therapeutics. Shareholders do not need to take any action, and the company's corporate structure will remain unchanged.